Understanding Prevention, Consultation, and Psychotherapy Research: Your Complete Guide
You're preparing to become a licensed psychologist in a world where mental health care is evolving rapidly. Understanding how we prevent mental health problems, consult with other professionals, and evaluate what actually works in therapy isn't just academic. It's the foundation of effective practice. Whether you're dreaming of private practice, working in a hospital, or joining a community mental health center, this knowledge shapes how you'll help people every single day.
The Three Faces of Prevention: Stopping Problems Before They Start
Caplan's Classic Prevention Model
Gerald Caplan gave us a framework that's stood the test of time since 1964. Think of prevention like maintaining your car: you can prevent problems before they happen, catch issues early when they're easier to fix, or manage damage after a breakdown.
Primary Prevention targets everyone, not just people who are struggling. The goal is stopping new cases from developing in the first place. These programs cast a wide net. A school district teaching all fifth graders how to handle the transition to middle school? That's primary prevention. A public education campaign about depression and suicide? Primary prevention. Prenatal care for low-income mothers? You guessed it. Primary prevention. You're helping people before problems even emerge.
Secondary Prevention gets more focused. Now you're identifying people who are at elevated risk and intervening early. It's like your phone's battery health warning. You're catching the problem before complete shutdown. When elementary school students start falling behind and receive tutoring, that's secondary prevention. When you use a screening test to identify people at risk for depression and offer them counseling, you're practicing secondary prevention. The key difference: you've identified specific at-risk individuals. To be precise, secondary prevention is for people already showing early or subclinical signs of a problem. A group that only shares a risk factor, like low-income mothers, can still receive primary prevention.
Tertiary Prevention comes into play when someone already has a diagnosis. Your goal shifts to reducing severity, preventing relapse, and supporting rehabilitation. Social skills training for patients with schizophrenia, halfway houses for people transitioning from addiction treatment, and Alcoholics Anonymous meetings all fall under tertiary prevention. You're managing an existing condition and preventing it from getting worse.
Gordon's Alternative Framework
Robert Gordon proposed a different way to slice the prevention pie in 1983, and his model gained serious traction.
Universal Prevention reaches everyone in a population without screening for risk. A drug abuse prevention program delivered to every single high school student in a district? That's universal. No one's screened out or specially selected.
Selective Prevention targets subgroups with elevated risk based on their characteristics. If you run that same drug abuse program but only for adolescents whose parents have substance use disorders, you've moved to selective prevention. You're choosing participants based on risk factors they didn't choose.
Indicated Prevention goes even further. You're working with individuals showing early warning signs of a disorder but who don't meet full diagnostic criteria yet. Adolescents who've experimented with drugs but haven't developed a substance use disorder? They're candidates for indicated prevention.
The Institute of Medicine later expanded Gordon's model into a full continuum that spans prevention, treatment, and maintenance. In their version, prevention (universal, selective, and indicated) is strictly for people without diagnoses. Once someone receives a diagnosis, you've moved into treatment. After treatment, maintenance strategies focus on preventing relapse and supporting rehabilitation.
Mental Health Consultation: When Other Professionals Need Your Expertise
Consultation is fundamentally different from treating your own clients. Think of it like being a technical advisor on a project rather than the project manager. You provide expertise but don't take direct responsibility for outcomes.
Caplan's Four Types of Consultation
Gerald Caplan (yes, him again) identified four distinct consultation types, each forming a triad: consultant (you), consultee (another professional or administrator), and client or program.
Client-Centered Case Consultation focuses on solving a problem with a specific client. A colleague texts you: "I'm stuck with this client. I can't figure out the right approach." You review the case and provide recommendations that will directly benefit that client. Your goal is giving the consultee a workable plan for this particular situation.
Consultee-Centered Case Consultation shifts focus to building the consultee's skills. Sure, there's a specific client who sparked the consultation, but your real aim is improving the consultee's ability to work with similar clients in the future. Maybe a therapist struggles with clients who have traumatic brain injuries. You're not just solving the immediate problem. You're teaching skills, building confidence, and addressing knowledge gaps. Caplan identified theme interference as a key obstacle here: when a consultee's biases and unfounded beliefs sabotage their objectivity with certain client types.
Program-Centered Administrative Consultation means working with administrators who are struggling with an existing mental health program. The program exists but has problems. Maybe like a website that's live but full of bugs. You help clarify issues and provide concrete recommendations for fixing program development, administration, or evaluation problems.
Consultee-Centered Administrative Consultation builds administrators' long-term capabilities. You're not just fixing today's program headaches. You're enhancing their professional skills so they can develop, run, and evaluate programs more effectively going forward.
Consultation vs. Collaboration: Know the Difference
Here's a critical distinction for the exam: consultants typically have minimal or no direct contact with the consultee's clients and aren't responsible for client outcomes. Collaborators, however, work directly with clients and share responsibility for what happens. A consultant is like a specialist who reviews medical records and suggests treatment options; a collaborator is part of the treatment team making decisions together.
Consulting on the Environment Itself: Environmental Psychology and Design
Psychologists also consult on physical spaces, not just cases and programs. Environmental psychology studies how the built environment shapes behavior and well-being, and it supplies the theory behind evidence-based design in health care: Ulrich's stress reduction theory, Kaplan's attention restoration theory, and the biophilia hypothesis (the idea that contact with nature restores us).
The findings worth knowing:
- Ulrich's classic study found surgical patients with a window view of nature had shorter stays and needed fewer strong pain medications than patients facing a brick wall. Windows and daylight are linked to better sleep, better orientation, and less delirium
- Noise is the single most disruptive factor for inpatient sleep, and hospitals routinely exceed recommended sound levels
- Single rooms improve sleep and privacy, though some patients prefer shared rooms to avoid loneliness
- In a randomized trial using simulated rooms viewed by previously hospitalized adults, both evidence-based design and feng shui-informed rooms reduced anxiety (the feng shui effect ran through pleasantness and perceived access to social support), while golden-ratio proportions did nothing. The lesson: design for pleasant, socially supportive spaces, not numerology
A psychologist advising a hospital or clinic on room design is acting as a consultant: providing research expertise, outcome measurement, and patient-centered co-design to administrators and architects, with no direct responsibility for individual patients. The usual rules travel with the role, including practicing within the boundaries of competence.
Interprofessional Collaboration: The Team Approach
Interprofessional collaboration (IPC) brings together healthcare providers and clients in a coordinated, participatory approach to shared decision-making. It's most common in primary care settings and aims to improve patient care, enhance health outcomes, and reduce costs.
The research shows mixed results, though. While most studies confirm IPC has positive effects on clinical outcomes, care processes, and patient satisfaction, the effects on quality of life and health behaviors aren't as consistent.
IPC shows particular promise for older adults with complex healthcare needs (often called integrated care in this context). Evidence suggests integrated care increases access, boosts satisfaction, and reduces emergency visits, hospitalizations, and long-term care placements. When you're juggling multiple health conditions in your 70s, having a coordinated team beats trying to navigate separate specialists who don't talk to each other.
Psycho-oncology: Helping People Live With Cancer
Cancer care covers more than the tumor. It also covers mood, thinking, daily life, and family. A psychologist works as part of the cancer care team, and the plan depends on the person's needs, symptoms, and stage of care (Riba et al., 2019).
Screen for Distress, Then Assess
The NCCN Distress Thermometer asks people to rate their distress from 0 to 10 for the past week. It comes with a Problem List. A score of 4 or more commonly prompts more assessment and help matched to the person's concerns. It does not diagnose depression. A low score does not rule out every serious problem, and cutoffs can work differently in different settings (Riba et al., 2019; Ma et al., 2014).
A distress score works like a smoke alarm. It tells you to go look. It does not tell you what is burning.
Cancer does not mean a person has a mental disorder. In interview studies in cancer settings, about 15% of patients had major depression and about 10% had an anxiety disorder. Numbers shift with the setting and the way problems are measured. Tiredness, poor appetite, and poor sleep can come from the illness or its treatment, so a screen should be followed by a real assessment (Mitchell et al., 2011).
Cancer-Related Cognitive Impairment
Some people with cancer have trouble with attention, memory, processing speed, and planning. People call it "chemo brain," but that name is incomplete. Thinking problems can occur before chemotherapy and may have several causes. They do not automatically mean Alzheimer's disease. Ask about daily functioning, use appropriate cognitive tests, and review medical and treatment factors with the care team. Testing again later shows whether things are changing (Lange et al., 2019; Wefel et al., 2011).
There is no single rate for all cancers. In one breast cancer review, the rate after chemotherapy depended on how it was measured: 44% with self-report, 16% with brief screens, and 21% to 34% with full test batteries. A person's complaint and a test score answer different questions (Whittaker et al., 2022).
Match the Therapy to the Problem
CBT and other talk therapies can ease distress and improve quality of life. Mindfulness-based stress reduction can lower depression and anxiety in the short term. Much of this research comes from breast cancer, and the benefits are not the same size for everyone (Jassim et al., 2023; Schell et al., 2019).
For advanced cancer, meaning-centered psychotherapy helps people explore meaning and purpose. CALM (Managing Cancer and Living Meaningfully) targets depression and the stress of serious illness. Both beat usual care in trials, but CALM did not beat supportive counseling in one head-to-head trial (Breitbart et al., 2018; Rodin et al., 2018; Mehnert et al., 2020).
Supportive-expressive group therapy helps people share feelings and get support. Do not promise that it will make someone live longer. Spiegel's early finding of longer survival did not hold up in his later trial. Reviews disagree: a 2024 review found no significant survival benefit, while a 2026 review found an average benefit with substantial variation across studies. Neither result guarantees longer life for an individual (Spiegel et al., 1989, 2007; Bognár et al., 2024; Asakawa-Haas et al., 2026).
Anticipatory Nausea: A Learning Example
After chemotherapy causes nausea a few times, the smell or sight of the clinic can trigger nausea before the next dose. The clinic has become a conditioned stimulus. Systematic desensitization pairs gradual exposure to these cues with relaxation. Progressive muscle relaxation is another supported behavioral method. These tools target the learned nausea and work alongside medical care (Morrow & Morrell, 1982; Figueroa-Moseley et al., 2007).
Fear of Recurrence and Life After Treatment
Fear that the cancer will come back can last long after treatment ends. Ask how much the fear gets in the way of daily life. Psychological treatments, including CBT that targets worry and attention, show small benefits for this fear. Survivorship care may also cover fatigue, sexual changes, relationships, and daily activities (Tauber et al., 2019; Lisy et al., 2019).
Keep Evidence Claims Honest
Stress can affect hormones, the immune system, and inflammation. Some studies link stress with cancer outcomes, but a link does not prove that stress caused someone's cancer. Positive thinking does not cure cancer (Chida et al., 2008; Lutgendorf & Sood, 2011).
Antidepressants may help depression in people with cancer, but the cancer-specific evidence is weak. Coordinate medicine choices with the prescriber and the oncology team. Psilocybin-assisted therapy is still experimental for cancer distress. Small trials paired it with structured therapy and found benefits, but reviews rate the evidence as low quality, and it is not FDA approved for this use (Vita et al., 2023; Griffiths et al., 2016; Ross et al., 2016; Schipper et al., 2024).
A promising early trial is like a great first date. It is a good sign, not a wedding.
Include the Family
Parents of children with cancer can benefit from psychosocial support. A meta-analysis found lower parent distress and better quality of life. Results for children who have finished cancer treatment are more mixed. Ask what each family member needs instead of assuming every family needs the same help (Ozturk et al., 2025; Arpaci & Altay, 2024).
Does Therapy Actually Work? The Evolution of Outcome Research
Eysenck's Bombshell (1952)
Hans Eysenck dropped a controversial paper claiming psychotherapy was not just ineffective but potentially harmful. He reviewed 24 studies of "neurotic" patients and compared outcomes to spontaneous remission rates from other studies. His conclusion: 72% of patients who didn't receive psychotherapy improved, compared to only 64% in eclectic therapy and 44% in psychoanalytic therapy.
The field exploded in response. Critics pointed out glaring flaws: patients weren't randomly assigned to groups, so initial differences could explain outcome differences. The criteria for "recovery" were questionable. Allen Bergin recalculated using different criteria and found 83% of psychoanalytic therapy patients improved versus only 30% of untreated patients. Eysenck's study, despite its flaws, sparked decades of rigorous outcome research.
Smith, Glass, and Miller's Meta-Analysis (1980)
These researchers pioneered using meta-analysis to combine results from 475 studies comparing therapy to no treatment. Their finding: an effect size of .85, meaning the average therapy patient was better off than 80% of people who didn't receive therapy. This was the empirical ammunition the field needed.
Howard's Dose-Effect and Phase Models
Howard and colleagues investigated how therapy duration relates to outcomes, producing two influential models:
The Dosage Model (dose-effect model) predicts a reliable relationship between session number and improvement probability. Expect 50% of clients to show clinically significant improvement by 6-8 sessions, 75% by 26 sessions, and 85% by 52 sessions.
The Phase Model describes therapy as moving through three stages:
- Remoralization (first few sessions): Hope increases
- Remediation (next 16 sessions): Symptoms decrease
- Rehabilitation (later sessions): Clients unlearn maladaptive patterns and develop new ways of functioning
The implication? Use different outcome measures for different phases. Measure subjective well-being early, symptom severity in the middle, and life functioning in later therapy.
What Makes Therapy Work? The Common Factors Debate
Since different therapy approaches produce similar benefits, researchers hunt for common elements that drive outcomes. Norcross and Lambert's research suggests this breakdown of what contributes to therapy outcomes:
- 30% patient contributions (motivation, resources, social support)
- 12% therapeutic relationship
- 8% treatment method
- 7% therapist characteristics
- 3% other factors
- 40% unexplained variance
The Working Alliance: Your Secret Weapon
Ralph Greenson first described the therapeutic relationship as having three components: working alliance, real relationship, and transference-countertransference. The working alliance (also called therapeutic alliance) has received the most research attention and is defined as the rational, non-neurotic relationship that allows purposeful work in therapy.
Research consistently identifies strong working alliances as significant predictors of successful outcomes. A recent meta-analysis confirmed this positive relationship holds across different assessors, measures, treatment approaches, patient characteristics, delivery modes (including internet-mediated therapy), and countries. The alliance is like the foundation of a house. You can have the best materials and blueprints, but without solid groundwork, nothing stands.
Client-Therapist Matching: Does It Matter?
The research on matching clients and therapists by race and ethnicity shows nuanced results. Matching has a moderate effect (.32) on how clients perceive their therapists but minimal effect (.09) on actual outcomes. Effects also vary by race/ethnicity, matching reduced premature termination for Asian, Hispanic, and European American clients but not African American clients, and only improved outcomes for Hispanic American clients.
More importantly, research suggests cultural competence, compassion, and worldview alignment matter more than ethnic matching itself.
For personality matching, some studies find that perceived similarity in traits like conscientiousness and openness to experience predicts stronger therapeutic relationships and better progress, though the effects are modest.
Who Uses Mental Health Services? Understanding Utilization Patterns
According to recent national surveys, several patterns emerge:
Gender: Women are more likely than men to take psychiatric medication and receive counseling.
Age: Adults 18-44 show the highest mental health treatment utilization, followed by those 45-64, then those 65+.
Sexual Orientation: Sexual minority (gay/lesbian and bisexual) individuals use mental health services at two to four times the rate of heterosexual individuals.
Race/Ethnicity: For outpatient services, people identifying as two or more races show highest utilization, followed by White individuals, with Asian individuals showing lowest rates. For inpatient services, people identifying as two or more races again show highest rates, followed by American Indian or Alaska Native individuals.
College Students: A Special Case
Mental health problems and service utilization have both increased among college students, yet most students with mental health problems still don't seek help even when available. Attitudinal barriers (preferring to handle it alone, wanting to talk to friends/family, embarrassment) are cited more often than structural barriers (cost, scheduling problems).
The stigma picture is complex: personal (self) stigma appears to be declining while perceived (public) stigma remains stable. Education-based and contact-based anti-stigma interventions show promise in improving attitudes toward treatment and willingness to seek help.
The Economics of Therapy: Does It Save Money?
Research confirms that psychological interventions often produce a medical cost offset. They reduce overall medical utilization and expenses. A meta-analysis of studies from 1967-1997 found that 90% of studies showed cost savings, with psychological interventions producing an average 20% reduction in medical costs. This is especially true for surgery patients, frequent healthcare users, and those with substance misuse or other psychological disorders.
Economic Evaluation Methods
Cost-Benefit Analysis (CBA) expresses both costs and benefits in monetary terms. You can directly compare whether spending $50,000 on a program generates $75,000 in benefits, like calculating ROI on an investment.
Cost-Effectiveness Analysis (CEA) compares costs when benefits can't be monetized, like comparing dropout rates or days worked.
Cost-Utility Analysis (CUA) measures costs per quality-adjusted life-year (QALY), combining quality and duration of life gains. Studies have shown that cognitive therapy and rational-emotive behavior therapy both have better cost-utility than fluoxetine for depression.
Mental Health Funding and Policy: How the System Got Here
The EPPP expects you to know the big policy landmarks that shaped how mental health care is funded and delivered in the US.
The Community Mental Health Centers Act (1963)
Signed by President Kennedy, this was the first federal law putting government directly in the business of delivering mental health services. It funded nearly 800 community mental health centers (CMHCs) as the alternative to institutionalization, each required to provide five essential services: inpatient care, outpatient care, emergency services, partial hospitalization, and consultation/education.
The catch: Congress never adequately funded staffing, and cuts (especially in the 1980s) left the community system chronically under-resourced.
Deinstitutionalization
Starting in the 1950s-60s, driven by antipsychotic medications, reactions to institutional abuses, and community-integration values, the census of psychiatric institutions collapsed from about 500,000 in 1955 to roughly 40,000 by the 2010s.
What the exam wants you to know about the aftermath:
- Community infrastructure never caught up. The plan was "close the hospitals, fund the community." Only the first half happened.
- Roughly a quarter to a third of homeless individuals have a serious mental illness
- Transinstitutionalization: many people moved from hospitals to jails and prisons rather than into community care
- Good community care turned out to be no cheaper than institutional care, contrary to the original selling point
The Mental Health Parity and Addiction Equity Act (MHPAEA, 2008)
The strongest federal parity law. Core rule: if a health plan covers mental health and substance use treatment, that coverage must be no more restrictive than its medical/surgical coverage. That applies to:
- Financial requirements: copays, coinsurance, deductibles
- Quantitative treatment limits: number of covered visits or inpatient days
- Nonquantitative treatment limits (NQTLs): prior authorization, utilization review, network restrictions, reimbursement rates
Two details that make good exam questions:
- MHPAEA does NOT require plans to cover mental health at all. It only requires parity IF they cover it. The Affordable Care Act (2010) closed much of that hole by making behavioral health an essential health benefit
- Enforcement is the weak spot: plans can look equal on paper while "managing away" benefits through aggressive utilization review and narrow provider networks (the NQTLs). Provider shortages compound the access problem. Over 150 million Americans live in designated mental health professional shortage areas
Mental Health Promotion and Prevention in Canada
The exam draws on Canadian psychology too (the EPPP licenses Canadian psychologists, and the ethics KNs name the CPA alongside the APA), so know the landmarks north of the border:
- Mental Health Commission of Canada (MHCC): an arm's-length national body created to drive mental health reform. In 2012 it released Changing Directions, Changing Lives, Canada's first national mental health strategy. Canada got its first national strategy decades after most industrialized countries because health care is run province by province, so nobody owned the national picture. The strategy is recovery-oriented, and its main documented success is consensus and policy adoption rather than measured population outcomes.
- Opening Minds: the MHCC's anti-stigma initiative, the largest systematic stigma-reduction effort in Canadian history. Its core method is contact-based education, where people with lived experience of mental illness share their recovery stories, aimed at four target groups: youth, health care providers, media, and workplaces. Evaluations show modest but consistent reductions in prejudicial attitudes, with contact-based education as the active ingredient.
- At Home/Chez Soi: the landmark multisite Housing First randomized trial, which enrolled over 2,000 homeless adults with mental illness across five Canadian cities. The strongest and most durable finding was housing stability; most health and quality-of-life outcomes did not differ from usual care over the long term, and no harms emerged.
The efficacy pattern to remember: strongest evidence for Housing First on housing stability, moderate evidence for contact-based stigma reduction, and mostly process-level evidence for the national strategy itself.
Efficacy vs. Effectiveness: Two Ways to Study Therapy
Efficacy studies (clinical trials) maximize internal validity, the ability to prove causation. They use random assignment, treatment manuals, and tight controls. These studies are like testing a new phone in a pristine lab where nothing interferes with the measurements.
Effectiveness studies maximize external validity (the ability to generalize findings. They occur in real-world clinical settings with all their messy complexity. This is testing that same phone in actual user conditions) dropped calls, multitasking, battery drain from countless apps.
The smart strategy? Start with efficacy research to establish that something works under ideal conditions, then move to effectiveness research to see if it works in real-world settings.
Moderators of Therapy Outcomes: What Really Matters?
Research on age, gender, and socioeconomic status shows they have minimal direct impact on therapy outcomes. Apparent differences typically result from other factors. For instance, low socioeconomic status sometimes links to premature termination, but that's usually due to transportation issues and other practical barriers, not the SES itself.
Research Biases to Watch For
Alpha bias exaggerates differences between men and women, potentially reinforcing stereotypes and justifying discrimination.
Beta bias minimizes or ignores differences, leading to the false assumption that research on one gender applies equally to the other.
Both biases can stem from androcentrism, viewing male behaviors and traits as the norm and female characteristics as deviations or deficiencies.
WEIRD sampling bias refers to over-reliance on samples from Western, Educated, Industrialized, Rich, and Democratic cultures. Research derived primarily from WEIRD samples may have limited generalizability. It's like developing a weather app based only on California data and assuming it works perfectly in Alaska.
Modern Advances in Treatment Delivery and Monitoring
Routine Outcome Monitoring (ROM)
ROM (also called feedback-informed treatment or measurement-based care) involves four components:
- Regularly administered measures before each session
- Practitioner reviews data
- Patient reviews data
- Collaborative treatment plan adjustments based on data
Studies show ROM increases clinically significant improvement rates and reduces client deterioration and premature termination, especially for clients at risk for treatment failure.
Despite benefits, many clinicians underutilize ROM due to barriers: clients worry about confidentiality and time requirements; clinicians question whether ROM beats clinical judgment, lack training, worry about effects on the therapeutic relationship, and have concerns about time demands and how employers/insurers will use the data.
Transdiagnostic Treatments
These treatments target commonalities across multiple diagnoses rather than focusing on single disorders. The premise: shared mechanisms matter more than diagnostic differences. Benefits include reduced training costs and better handling of comorbidities.
Research generally confirms transdiagnostic treatments match or exceed single-diagnosis treatments in effectiveness. Examples include:
- CBT-Enhanced (CBT-E) for eating disorders
- Unified Protocol (UP) for anxiety, depression, and related disorders
- Emotion-Focused Therapy-Transdiagnostic (EFT-T) for depression, anxiety, and related disorders
- Acceptance and Commitment Therapy (ACT) for wide-ranging conditions
- Parent-Child Interaction Therapy (PCIT) for childhood disorders
Telepsychology: Therapy in the Digital Age
Telepsychology delivers psychological services via telephone, video, email, chat, text, and internet platforms. It offers major advantages: reduced costs, increased access (especially for rural/underserved populations), and decreased stigma.
The research shows promising results across disorders:
Anxiety Disorders: Videoconference-delivered CBT shows effectiveness comparable to in-person therapy for panic disorder, generalized anxiety disorder, and social anxiety disorder.
PTSD: Trauma-focused therapies delivered via telepsychology match face-to-face interventions in symptom reduction, attendance, dropout rates, and satisfaction. Some therapists report challenges developing therapeutic alliance due to difficulty detecting nonverbal communication.
Depression: Most studies show significant symptom decreases following videoconference therapy with no significant differences from in-person treatment. Telepsychology also helps with comorbid insomnia and chronic pain.
Bulimia Nervosa: Results are more mixed. While telepsychology-delivered treatments produce beneficial effects, in-person CBT sometimes shows advantages for abstinence rates and reducing eating-disordered cognitions. The challenge? Regular weight monitoring (a key CBT component) becomes logistically difficult via video.
Despite benefits, psychologists report challenges: internet connectivity issues, general technical difficulties, patients finding private spaces, diminished therapeutic alliance, and privacy concerns.
Digital Mental Health Interventions (DMHI)
DMHIs use online and mobile formats to deliver psychological strategies. From simple mood tracking apps to comprehensive CBT programs. Randomized controlled trials show they can match face-to-face therapy outcomes, but implementation research in healthcare settings shows less impressive results. The culprits? Inconsistent patient use, provider uncertainty about engagement strategies, and unclear integration into overall care.
One consistent finding: human support helps. Meta-analyses show that 22 of 45 effect sizes indicated support significantly improved outcomes, and 13 more showed non-significant trends toward benefit. Interestingly, professional versus nonprofessional support made little difference.
Stepped Care: Matching Intensity to Need
Stepped care delivers the least restrictive treatment likely to produce significant benefit, with systematic monitoring and "stepping up" if needed. For depression, common models include:
| Step | Intervention | Who It's For |
|---|---|---|
| 1 | Assessment and "watchful waiting" | Minor symptoms |
| 2 | Psychoeducation, bibliotherapy, computer-based interventions | Mild symptoms or prevention |
| 3 | Group therapy, individual psychotherapy, medication | Moderate symptoms |
| 4 | Inpatient care | Severe symptoms |
The goals: increase efficiency and accessibility by better allocating scarce mental health resources.
Treatment Fidelity: Doing It Right
Treatment fidelity measures how well a treatment is delivered as intended, affected by therapist adherence to protocols and competence. High fidelity matters for both research (can't evaluate effectiveness without it) and practice (can't know if poor outcomes reflect implementation problems or treatment problems).
Research confirms that interventions working well in controlled trials may fail in real-world contexts when fidelity drops.
Models of Disability: Shifting Perspectives
The Americans with Disabilities Act defines disability broadly: having an impairment that substantially limits a major life activity, having a record of such impairment, or being regarded as having one.
Biomedical Model (Medical Model): Views disabilities as medical conditions deviating from normal functioning. Disabilities are intrinsic to individuals; treatment focuses on managing, altering, or curing the condition.
Social Model: Views disabilities as differences, not deficiencies, caused primarily by societal barriers (negative attitudes, discrimination, architectural barriers). Intervention focuses on changing society and environments.
Functional Model: Views disabilities as causing inability to perform roles or functions. Recognizes medical conditions but focuses on accommodations, modifications, and assistive technology to improve functioning.
Forensic Model: Focuses on legal concepts, requiring objective proof of impairment and determining honesty and motivation of people seeking benefits or compensation. The aim is distinguishing honest claims from malingering.
Common Misconceptions Students Should Avoid
Misconception #1: "Primary prevention is always the most important type of prevention."
Reality: All three levels matter. Primary prevents problems from starting, secondary catches them early, and tertiary prevents existing problems from worsening. You need all three in a comprehensive mental health system.
Misconception #2: "Consultants and collaborators are basically the same thing."
Reality: Consultants rarely have direct client contact and aren't responsible for outcomes. Collaborators work directly with clients and share responsibility. This distinction appears on the exam.
Misconception #3: "Therapy research shows that the specific technique matters most."
Reality: Treatment method accounts for only 8% of outcome variance. Patient contributions (30%) and therapeutic relationship (12%) matter more. This doesn't mean technique is irrelevant, but relationship factors are crucial.
Misconception #4: "Matching client and therapist ethnicity guarantees better outcomes."
Reality: The research shows small effects on client perceptions (.32) but minimal effects on actual outcomes (.09), varying by client race/ethnicity. Cultural competence matters more than matching.
Misconception #5: "Telepsychology is always less effective than in-person therapy."
Reality: For most conditions, research shows comparable effectiveness. Some challenges exist (technical issues, detecting nonverbal cues), but outcomes are generally similar when implemented properly.
Practice Tips for Remembering This Material
For Prevention Models: Create a comparison table in your notes showing Caplan's three types side-by-side with Gordon's three types. Notice that Caplan's model moves from whole populations to diagnosed individuals, while Gordon's model moves from universal to those showing early signs (all before diagnosis).
For Consultation Types: Use the acronym "CC-PP" (Client-Client, Consultee-Consultee, Program-Program, Program-Consultee) to remember that Caplan has two case types and two administrative types, with each focused either on the immediate problem or building consultee skills.
For Outcome Research: Remember chronologically: Eysenck said therapy doesn't work (1952), Smith/Glass/Miller proved it does with meta-analysis (1980), and Howard described how long it takes (1986, 1996).
For Common Factors: Remember the big three. Patient contributions are biggest (30%), therapeutic relationship matters (12%), and specific technique matters least (8%) of the identified factors.
For Economic Evaluation: Match the analysis type to what you're measuring: CBA = both in $, CEA = costs in $ but effects can't be monetized, CUA = costs per QALY (quality and duration combined).
Key Takeaways
- Prevention comes in levels: Caplan's primary/secondary/tertiary and Gordon's universal/selective/indicated offer complementary frameworks for understanding prevention strategies
- Consultation ≠ Collaboration: Consultants advise without direct client contact or outcome responsibility; collaborators work directly with clients and share responsibility
- Therapy works: Despite Eysenck's controversial claims, meta-analyses confirm therapy produces significant benefits (effect size .85 = better than 80% of untreated individuals)
- Common factors matter more than technique: Patient contributions (30%) and therapeutic relationship (12%) outweigh specific treatment method (8%) in predicting outcomes
- The working alliance is crucial: Consistently predicts successful outcomes across treatment types, populations, and delivery modes
- Demographics have minimal direct impact: Age, gender, and SES show little direct effect on outcomes when confounds are controlled
- Telepsychology is effective: Research shows comparable outcomes to in-person therapy for most conditions, with added benefits of accessibility and reduced costs
- Stepped care increases efficiency: Delivering the least restrictive effective treatment with systematic monitoring optimizes resource allocation
- Treatment fidelity matters: Both research validity and clinical effectiveness depend on delivering treatment as intended
- Multiple disability models exist: Biomedical, social, functional, and forensic models offer different perspectives on disability and inform different intervention approaches
- Policy landmarks: Community Mental Health Centers Act (1963) launched community care; deinstitutionalization emptied hospitals without funding the replacement (homelessness, transinstitutionalization); MHPAEA (2008) requires parity only IF mental health is covered, with the ACA making it an essential benefit; NQTLs are the enforcement loophole
- A Distress Thermometer score of 4 or more prompts more assessment; it does not diagnose depression.
- Cancer-related cognitive problems can start before chemotherapy; assess daily function and cognition and review medical factors.
- Anticipatory nausea is a conditioned response; systematic desensitization and progressive muscle relaxation target it.
- Support groups can ease distress, but reviews disagree on survival, so longer life cannot be promised.
This material forms the foundation for evidence-based practice. Whether you're preventing problems, consulting with colleagues, delivering therapy, or evaluating outcomes, these principles guide effective, ethical, and efficient mental health care.
Sources added 2026-10-20
- Arpaci, T., & Altay, N. (2024). Psychosocial interventions for childhood cancer survivors: Systematic review and meta-analysis of randomized control trials. European Journal of Oncology Nursing, 69, 102541. PMID 38460392. https://pubmed.ncbi.nlm.nih.gov/38460392/
- Asakawa-Haas, K. D., Spiegel, D., Bossert, L., et al. (2026). Psychosocial interventions indicate prolonged survival in cancer patients in a systematic review, meta-analysis, and multiverse meta-analysis of randomized controlled trials. Communications Psychology, 4(1), 49. PMID 41673256. https://pubmed.ncbi.nlm.nih.gov/41673256/
- Bognár, S. A., Teutsch, B., Bunduc, S., et al. (2024). Psychological intervention improves quality of life in patients with early-stage cancer: A systematic review and meta-analysis. Scientific Reports, 14(1), 13233. PMID 38853187. https://pubmed.ncbi.nlm.nih.gov/38853187/
- Breitbart, W., Pessin, H., Rosenfeld, B., et al. (2018). Individual meaning-centered psychotherapy for the treatment of psychological and existential distress: A randomized controlled trial in patients with advanced cancer. Cancer, 124(15), 3231-3239. PMID 29757459. https://pubmed.ncbi.nlm.nih.gov/29757459/
- Chida, Y., Hamer, M., Wardle, J., & Steptoe, A. (2008). Do stress-related psychosocial factors contribute to cancer incidence and survival? Nature Clinical Practice Oncology, 5(8), 466-475. PMID 18493231. https://pubmed.ncbi.nlm.nih.gov/18493231/
- Figueroa-Moseley, C., Jean-Pierre, P., Roscoe, J. A., et al. (2007). Behavioral interventions in treating anticipatory nausea and vomiting. Journal of the National Comprehensive Cancer Network, 5(1), 44-50. PMID 17239325. https://pubmed.ncbi.nlm.nih.gov/17239325/
- Griffiths, R. R., Johnson, M. W., Carducci, M. A., et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181-1197. PMID 27909165. https://pubmed.ncbi.nlm.nih.gov/27909165/
- Jassim, G. A., Doherty, S., Whitford, D. L., & Khashan, A. S. (2023). Psychological interventions for women with non-metastatic breast cancer. Cochrane Database of Systematic Reviews, CD008729. PMID 36628983. https://pubmed.ncbi.nlm.nih.gov/36628983/
- Lange, M., Joly, F., Vardy, J., et al. (2019). Cancer-related cognitive impairment: An update on state of the art, detection, and management strategies in cancer survivors. Annals of Oncology, 30(12), 1925-1940. PMID 31617564. https://pubmed.ncbi.nlm.nih.gov/31617564/
- Lisy, K., Langdon, L., Piper, A., & Jefford, M. (2019). Identifying the most prevalent unmet needs of cancer survivors in Australia: A systematic review. Asia-Pacific Journal of Clinical Oncology, 15(5), e68-e78. PMID 31215167. https://pubmed.ncbi.nlm.nih.gov/31215167/
- Lutgendorf, S. K., & Sood, A. K. (2011). Biobehavioral factors and cancer progression: Physiological pathways and mechanisms. Psychosomatic Medicine, 73(9), 724-730. PMID 22021459. https://pubmed.ncbi.nlm.nih.gov/22021459/
- Ma, X., Zhang, J., Zhong, W., et al. (2014). The diagnostic role of a short screening tool, the distress thermometer: A meta-analysis. Supportive Care in Cancer, 22(7), 1741-1755. PMID 24510195. https://pubmed.ncbi.nlm.nih.gov/24510195/
- Mehnert, A., Koranyi, S., Philipp, R., et al. (2020). Efficacy of the Managing Cancer and Living Meaningfully (CALM) individual psychotherapy for patients with advanced cancer: A single-blind randomized controlled trial. Psycho-Oncology, 29(11), 1895-1904. PMID 32803815. https://pubmed.ncbi.nlm.nih.gov/32803815/
- Mitchell, A. J., Chan, M., Bhatti, H., et al. (2011). Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: A meta-analysis of 94 interview-based studies. The Lancet Oncology, 12(2), 160-174. PMID 21251875. https://pubmed.ncbi.nlm.nih.gov/21251875/
- Morrow, G. R., & Morrell, C. (1982). Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. The New England Journal of Medicine, 307(24), 1476-1480. PMID 6128673. https://pubmed.ncbi.nlm.nih.gov/6128673/
- Ozturk, C. S., San, E. G., & Yildiz, S. (2025). Effectiveness of psychosocial interventions on stress, anxiety, depression, and quality of life in parents of children, adolescents, and young adults with cancer: A meta-analysis of RCTs. Nursing & Health Sciences, 27(2), e70156. PMID 40494515. https://pubmed.ncbi.nlm.nih.gov/40494515/
- Riba, M. B., Donovan, K. A., Andersen, B., et al. (2019). Distress management, version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 17(10), 1229-1249. PMID 31590149. https://pubmed.ncbi.nlm.nih.gov/31590149/
- Rodin, G., Lo, C., Rydall, A., et al. (2018). Managing Cancer and Living Meaningfully (CALM): A randomized controlled trial of a psychological intervention for patients with advanced cancer. Journal of Clinical Oncology, 36(23), 2422-2432. PMID 29958037. https://pubmed.ncbi.nlm.nih.gov/29958037/
- Ross, S., Bossis, A., Guss, J., et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165-1180. PMID 27909164. https://pubmed.ncbi.nlm.nih.gov/27909164/
- Schell, L. K., Monsef, I., Wöckel, A., & Skoetz, N. (2019). Mindfulness-based stress reduction for women diagnosed with breast cancer. Cochrane Database of Systematic Reviews, CD011518. PMID 30916356. https://pubmed.ncbi.nlm.nih.gov/30916356/
- Schipper, S., Nigam, K., Schmid, Y., et al. (2024). Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases. Cochrane Database of Systematic Reviews, CD015383. PMID 39260823. https://pubmed.ncbi.nlm.nih.gov/39260823/
- Spiegel, D., Bloom, J. R., Kraemer, H. C., & Gottheil, E. (1989). Effect of psychosocial treatment on survival of patients with metastatic breast cancer. The Lancet, 2(8668), 888-891. PMID 2571815. https://pubmed.ncbi.nlm.nih.gov/2571815/
- Spiegel, D., Butler, L. D., Giese-Davis, J., et al. (2007). Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: A randomized prospective trial. Cancer, 110(5), 1130-1138. PMID 17647221. https://pubmed.ncbi.nlm.nih.gov/17647221/
- Tauber, N. M., O'Toole, M. S., Dinkel, A., et al. (2019). Effect of psychological intervention on fear of cancer recurrence: A systematic review and meta-analysis. Journal of Clinical Oncology, 37(31), 2899-2915. PMID 31532725. https://pubmed.ncbi.nlm.nih.gov/31532725/
- Vita, G., Compri, B., Matcham, F., Barbui, C., & Ostuzzi, G. (2023). Antidepressants for the treatment of depression in people with cancer. Cochrane Database of Systematic Reviews, CD011006. PMID 36999619. https://pubmed.ncbi.nlm.nih.gov/36999619/
- Wefel, J. S., Vardy, J., Ahles, T., & Schagen, S. B. (2011). International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. The Lancet Oncology, 12(7), 703-708. PMID 21354373. https://pubmed.ncbi.nlm.nih.gov/21354373/
- Whittaker, A. L., George, R. P., & O'Malley, L. (2022). Prevalence of cognitive impairment following chemotherapy treatment for breast cancer: A systematic review and meta-analysis. Scientific Reports, 12(1), 2135. PMID 35136066. https://pubmed.ncbi.nlm.nih.gov/35136066/
